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Abstract
The tumor-initiating cell (TIC) frequency of bulk tumor cell populations is one of the criteria used to distinguish
malignancies that follow the cancer stem cell model from those that do not. However, tumor-initiating cell frequencies may
be influenced by experimental conditions and the extent to which tumors have progressed, parameters that are not always
addressed in studies of these cells. We employed limiting dilution cell transplantation of minimally manipulated tumor cells
from mammary tumors of several transgenic mouse models to determine their tumor-initiating cell frequency. We
determined whether the tumors that formed following tumor cell transplantation phenocopied the primary tumors from
which they were isolated and whether they could be serially transplanted. Finally we investigated whether propagating
primary tumor cells in different tissue culture conditions affected their resident tumor-initiating cell frequency. We found
that tumor-initiating cells comprised between 15% and 50% of the bulk tumor cell population in multiple independent
mammary tumors from three different transgenic mouse models of breast cancer. Culture of primary mammary tumor cells
in chemically-defined, serum-free medium as non-adherent tumorspheres preserved TIC frequency to levels similar to that
of the primary tumors from which they were established. By contrast, propagating the primary tumor cells in serum-
containing medium as adherent populations resulted in a several thousand-fold reduction in their tumor-initiating cell
fraction. Our findings suggest that experimental conditions, including the sensitivity of the transplantation assay, can
dramatically affect estimates of tumor initiating cell frequency. Moreover, conditional on cell culture conditions, the tumor-
initiating cell fraction of bulk mouse mammary tumor cell preparations can either be maintained at high or low frequency in
vitro thus permitting comparative studies of tumorigenic and non-tumorigenic cancer cells.
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Introduction
Tumor-initiating cells (TICs), often termed cancer stem cells,
are functionally defined by their capacity to re-grow a new tumor
after transplant into experimental animals that recapitulates the
phenotype of the primary tumor from which the cells were
isolated, and which can be serially transplanted thus demonstrat-
ing their capacity to differentiate and self-renew [1]. TICs were
first identified in acute myelogenous leukemia [2], and thereafter
in many solid tumors [3–7] including those of the breast [8]. TICs
and tissue-specific adult stem cells share phenotypic and functional
properties leading to the suggestion that they originate from adult
stem cells or from progenitor cells that acquire stem cell traits [9–
11]. TICs are infrequent in most human tumors, rarely exceeding
0.01% of the bulk tumor cell population [3–6,8,12,13]. However,
recent findings in mouse cancer models [14–20] and human
melanomas [21] demonstrate that TIC frequencies can approach
25% of the bulk tumor cell population calling into question the
generality of the cancer stem cell model. However, various
parameters influence TIC frequency in bulk tumor cell prepara-
tions including the methods used to isolate and process tumor
samples, the site of tumor cell injection, the extent of the immune-
deficiency of the recipient host, the duration of the observational
period following tumor cell transplant, and whether agents that
facilitate tumor cell engraftment such as Matrigel or stromal cells
are co-injected with the tumor cells [21]. Hence the frequency of
TICs in tumors is insufficient to distinguish malignancies that
follow the cancer stem cell model from those that do not.
Studies of human breast TICs are challenging for a number of
reasons. Breast tumors are generally small at the time of resection
thus providing relatively few bulk tumor cells for TIC purification
and analyses [8]. Moreover, current cell purification methods yield
TIC preparations that at best comprise ,1–2% of the total tumor
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cell population thus compromising their specific study [8,22]. To
overcome these limitations we investigated whether mammary
tumors of transgenic mice might afford a more plentiful and
renewable source of TICs for investigation. Whereas the available
mouse models of breast cancer do not wholly reproduce the
diversity of human breast tumor subtypes, in part because most
mouse mammary tumors rarely express the estrogen receptor,
morphological analyses [23,24], biomarker studies [25] and global
transcript profiling [26] suggests that they provide approximate
replicas of their human subtype counterparts. For example,
mammary tumors occurring in the Neu and polyomavirus middle
tumor antigen (mT) models are morphologically similar to certain
human breast tumor histological subtypes [24,25], and share
a gene expression signature characteristic of the luminal molecular
subclass of human breast tumors [26]. Similarly mouse mammary
tumors resulting from overexpression of Wnt/beta (b) – catenin
pathway components mimic those of the basal-like molecular
subtype of human breast tumors [26].
Mouse mammary TICs have been identified in p53-null mice
and in transgenic mice genetically engineered to overexpress Wnt-
1 or Neu (Erbb2 or Her-2) in their mammary epithelium [17–20].
The TIC frequency among tumors from each of the models varies
between 0.01%–1% of the bulk tumor cell population. Whereas
the frequency of TICs in different tumors arising in the same
model as determined by an individual research group is roughly
equivalent, different laboratories report up to 50-fold differences in
TIC frequencies in tumors arising in the same model [17–20,27].
For example, the TIC frequency reported by Vaillant et al in
tumors of a Wnt-1 transgenic strain (0.56%) supersedes that
reported by Cho et al (0.013%) by over 40 fold [17,19].
We employed several mouse models of human breast cancer,
where the mouse mammary tumor virus (MMTV) promoter
directs transcription of the rat neu proto-oncogene [28] or
oncogenes encoding either mT [29] or a stable mutant form of
b-catenin in mammary epithelial cells to determine their tumor-
resident TIC frequency and to learn whether this parameter
differed among the models. The tumors arising in the transgenic
strains display characteristic histopathologies, vary in their cellular
composition and have been inferred to originate from the
oncogenic transformation of mammary epithelial stem cells or
particular progenitor cells [30,31]. Neu-induced tumors comprise
a relatively homogenous tumor cell population that primarily
expresses luminal-lineage markers [24], whereas tumors induced
by expression of mT or by activation of the Wnt/b-catenin
pathway are heterogeneous comprising both luminal- and
myoepithelial-lineage-biased cells [8,24,30,32]. The extent of the
cellular heterogeneity of Wnt-1 induced tumors varies among
individual tumors [24] and that of the mT-generated tumors
increases during their progression [25].
We determined the TIC fraction in multiple mammary tumors
arising in each of the models and found that, independent of the
model, all the tumors comprised between 15% and 50% TICs.
Culture of primary tumor cells from tumors of the MMTV-Neu
model in serum-free medium, conducive for stem cell self-renewal
[33], led to the formation of non-adherent spheres, termed
tumorspheres [34], that comprised a TIC frequency similar to that
of the tumor from which the cells were isolated. By contrast, when
the primary tumor cells were placed in serum-containing medium,
conditions that initiate a differentiation program in human and
mouse mammary epithelial stem/progenitor cells [35,36,37,38],
the tumor cells adhered to the substratum and proliferated
resulting in the net expansion of the tumor cell population, but the
TIC frequency declined by multiple orders of magnitude
compared to that in bulk primary tumor cells. Hence, the mouse
mammary tumors we have investigated provide an abundant and
renewable tumor cell populations, which can be manipulated in
vitro to derive TIC-rich or -poor cell populations for comparative
studies.
Materials and Methods
Care and treatment of mice
All mice used in these experiments were housed in an Canadian
Council on Animal Care (CCAC)-approved facility at McMaster
University. Mice were provided with food and water ad libitum. All
animal experiments were approved by the McMaster University
Animal Research Ethics Board (AUP: 10-01-04).
Isolation and transplant of primary tumor cells
We have reported the methods used to isolate, process and
transplant mammary epithelial cells and tumor cells [38,39]. In
short, tumors were surgically removed from anesthetized trans-
genic female mice and minced with a scalpel in Versene. Roswell
Park Memorial Institute (RPMI) medium containing trypsin
(1 mg/ml) and collagenase A (3 mg/ml) and 2% fetal bovine
serum (FBS) were added and the tissue fragments incubated for
15 minutes at 37uC. The tumor cell suspension was titruated by
repeated pipetting with a 5 ml pipette and incubated for another
15-minute period at 37uC. The tumor cell suspension was titruated
again at the end of the second incubation period and the
dissociated cells were filtered through 40 mm cell strainers (Falcon;
Franklin Lakes, NJ USA) and concentrated by centrifugation at
1,500 rpm for 15 minutes at room temperature. Cells were
washed in 50 ml volumes of Ham’s F12 (Invitrogen; Carlsbad
CA, USA) until the supernatant was clear of red blood cells. The
cells were stained with trypan blue and the fraction of viable cells
calculated using a hemocytometer. Approximately 90–95% of the
cells prepared from tumors were viable as visualized microscop-
ically. Cells to be injected into the ‘‘cleared’’ number 4 mammary
fat pad were suspended in 50% Matrigel (BD Biosciences; Bedford
MA, USA) (in phosphate-buffered saline [PBS] supplemented with
5% FBS and 0.5% trypan blue). Ten microliters of the Matrigel/
cell suspension were injected into the cleared fat pads of recipient
females. When single cells were injected, the cells were diluted to
0.1 cell/microliter and the occurrence of a single cell in 10
microliters of this solution deposited in a Terasaki plate was
confirmed microscopically before injecting the sample. Mice
transplanted with tumor cells were examined for tumors at either
4 or 16 weeks post cell transplantation and were scored positive if
any tumor-like masses were observed. TIC frequencies for single-
cell seeded tumors were determined using ELDA software (http://
wehi.edu.au/software/elda/index.html [40], whereas TIC fre-
quency of the adherent tumor cell population was estimated using
L-calc Software (Stem Cell Technologies; Vancouver BC,
Canada).
Whole mount analyses
Mammary fat pads from recipient mice were spread onto glass
slides, allowed to air-dry and subsequently stained in Harris
Haematoxylin (Fisher Scientific; Fair Lawn NJ, USA). Excess stain
was removed from the whole mounts by washes in 70% ethanol
and 1% hydrochloric acid, and were dehydrated in 100% ethanol,
cleared in xylenes and mounted on glass slides with Permount
(Fisher Scientific). Stained whole mounts were examined on
a Leica Diaplan (Leica; Concord ON, Canada) dissecting
microscope and photographed.
Breast Tumor-Initiating Cells from Mouse Models
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Histology
Tumors were fixed in 4% paraformaldehyde (EM Science;
Gibbstown NJ, USA) for 24 hours at room temperature,
embedded in paraffin, cut into 4 mm sections and stained with
Harris Haematoxylin and Eosin (H&E) solution. All images were
captured using a Leica inverted microscope (Leica) and Open Lab
Improvision software (Perkin Elmer; San Jose CA, USA).
Immunoflorescent staining. The expression of mammary
epithelial cell lineage markers in tumor sections was determined as
described previously [38]. In brief, antigen retrieval was performed
on tumor sections using Antigen Unmasking solution (Vector
Labs; Burlingame CA, USA) prior to blocking in 3% normal goat
serum (Dako Cytomations; Carpinteria CA, USA). All antibody
incubations were performed for 1 hour at room temperature. The
primary antibodies included those that bind to alpha-smooth
muscle actin (a-Sma) (mouse monoclonal, Sigma; Saint Louis MO,
USA), cytokeratin (CK) 14 (rabbit polyclonal, Covance; Emery-
ville CA, USA), and CK8 (rat monoclonal, Developmental Studies
Hybridoma Bank; Iowa City IA, 52242 USA). Alexa Fluor – 488
or Alexa Fluor- 594 conjugated secondary antibodies were used in
conjunction with the goat anti-rat and goat anti-rabbit primary
antibodies. The Alexa Fluor – 488, signal-amplification kit
(Molecular Probes, Eugene OR, USA) was used to detect the
primary mouse monoclonal antibody bound to a-Sma (Sigma).
Slides were prepared with Vecta-shield mounting media contain-
ing 49, 69- diamindino-2-phenylindole (DAPI) (Vector Laborato-
ries) to visualize nuclei.
Culture of tumor cells in vitro
Freshly isolated primary tumor cells were placed in serum-free
medium comprising Dulbecco Modified Eagle Medium (DMEM):
Ham’s F-12 (3:1), 4 mg/ml of B-27, 20 ng/ml Epidermal Growth
Factor (EGF), 40 ng/ml Fibroblast Growth Factor-2 (FGF-2) and
4 ng/ml Heparin, and plated into ordinary T25 tissue culture
flasks (all from Invitrogen) to generate tumorspheres [33]. The
primary tumorspheres that arose 4 days later were mechanically
dissociated (titruation) to derive a single cell suspension and the
dispersed cells plated in serum-free medium containing the growth
factors described above at a density of ,30,000 cells per ml; this
process was repeated for a total of 3 serial passages [38]. The cells
were dissociated by titruation from the serially-passaged tumor-
spheres prior to their injection into mice as described above.
Dispersed primary tumor cells were similarly plated into T25 flasks
in serum-containing medium (DMEM containing 10% FBS). The
adherent cells were epithelial in morphology suggesting they
originated from tumor epithelial cells; fibroblastic cells were not
apparent in these cultures. The tumor cells were removed from the
plastic surface using trypsin (0.25% in Versene) at 37uC, diluted in
serum-containing medium and plated as described above. The
adherent tumor cells were passaged every 4 days for 3 passages
before measuring their TIC frequency as described above. Use of
different serum lots did not affect the TIC frequency of the
adherent cultures.
Results
Initial limiting dilution tumor cell transplant experiments were
carried out with mammary tumors from transgenic mice of the
MMTV-Neu (N202) strain that express the wild type rat Neu
cDNA in mammary epithelial cells [28]. Tumors arise in this
model after long latency (,315 days in 50% of virgin female mice)
[39] due in part to deletions in the Neu cDNA encoding the juxta-
membrance region of the protein leading to constitutive activation
of its tyrosine kinase activity [41,42]. To estimate the frequency of
TICs in these tumors, limiting dilutions of dispersed primary
tumor cells were transplanted into the mammary fat pads of
syngeneic FVB/N mice. The mice were sacrificed 4 weeks later, at
a time when palpable tumors had developed in animals injected
with 104 or 105 tumor cells. Small tumor-like masses, which we
termed tumor nodules, were found near the cell injection site,
corresponding in size to the number of transplanted tumor cells
(Fig. 1 A, black arrows). Unexpectedly, tumor nodules were found
in mice transplanted with single cells. The masses resulting from
transplant of between 5 and 100 tumor cells appeared to be
a collection of individual nodules resembling those that had
formed in fat pads injected with a single cell. Nodules approxi-
mating the size of those seeded by single cells were often observed
along the needle track (Fig. 1A, white arrows). These findings
suggested that single transplanted tumor cells proliferated in the
mammary fat pads of their host thereby forming nodules, and that
transplant of multiple tumor cells into individual fat pads yielded
aggregates of multiple nodules.
To learn whether the tumor nodules appearing in mice
transplanted with single cells were indeed nascent tumors and
could form bona fide tumors, we repeated the transplants with cells
from a different mammary tumor and sacrificed the recipient hosts
4 or 16 weeks thereafter. Single tumor cells, visualized micro-
scopically prior to transplant, were injected into syngeneic female
mice. Tumor nodules were found in many of the recipients
4 weeks after cell transplantation as observed previously (Fig. 1B),
whereas large tumors were apparent 16 weeks post cell trans-
plantation (Fig. 1 C and D). These findings suggest that the tumor
nodules observed 4 weeks post-transplantation progress to form
large tumors 16 weeks after the initial transplant of single primary
tumor cells.
To determine the frequency of TIC in individual mammary
tumors and to learn whether this fraction varied among the
tumors, we performed limiting dilution cell transplants with tumor
cells from additional independent Neu-induced tumors. Tumors
were present 16 weeks post transplant in 20 of 40 host mice
inoculated with single tumor cells from each of 6 independent
Neu-induced mammary tumors (Table 1). The TIC frequency
calculated from single cell transplants ranged from 1/2–1/6 (95%
confidence interval [95% CI]) [43]. Limiting dilution cell trans-
plantation experiments were also performed with 2 mammary
tumors that arose in mT transgenic mice and 3 that formed in the
stable b-catenin transgenic strain. The TIC fraction in these
tumors averaged 1/3 (1/2–1/6; 95% CI) for the mT model and
1/3 (1/2–1/8; 95% CI) for the stable b catenin model.
To learn whether tumors arising after single cell transplants
recapitulated the phenotype of the tumor from which they were
derived, we compared the histology and cellular composition of
the tumors in the transgenic strains with those occurring in the
mice transplanted with genetically matched individual tumor cells
from the same parent tumors. Antibodies to a luminal-lineage
marker (CK8) and those to each of two myoepithelial-lineage
markers (CK14 and a-SMA) were used to characterize the cellular
composition of the tumors. The morphology and cellular
composition of the mammary tumors in the Neu (Fig. 2 A–C
subpanel 1) and mT (Fig. 3 A–C subpanel 1) transgenic mice was
similar to that reported previously [24,25,44]. The tumors arising
from transplants of single tumor cells isolated from tumors
occurring in each model (Neu and mT) reproduced the
histopathology (Fig. 2A subpanel 2, and Fig. 3A subpanel 2) of
the corresponding parental tumors. Similarly the cellular compo-
sition of the tumors originating in mice transplanted with single
Neu-tumor cells (Fig. 2B subpanel 2 and Fig. 2C subpanel 2), or
single mT-tumor cells (Fig. 3B subpanel 2 and Fig. 3C subpanel 2)
Breast Tumor-Initiating Cells from Mouse Models
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reproduced that of the corresponding parental tumors. Whereas
the mammary tumors in mice resulting from activation of the
Wnt/b-catenin pathway span a range of morphologies and vary in
their proportion of luminal-lineage and myoepithelial-lineage
restricted cells, the tumor-specific characteristics of each primary
tumor was reproduced in secondary tumors seeded by individual
tumor cells that had been isolated from the same primary tumor
(Fig. 4, compare panels 1 and 2).
To determine whether the tumors resulting from single cell
transplants comprised self-renewing TIC, we performed serial
transplants of the engrafted tumors [45,46]. Tissue fragments
(,1 mm3) comprising ,5,000 tumor cells from the single cell-
seeded tumors from each of the three models formed secondary
tumor grafts in over 80% of transplanted hosts, which could be
similarly serially transplanted for up to 10 successive passages
before this experiment was discontinued (data not shown). Hence
the tumors of all three breast-cancer prone mouse models
comprised TIC capable of recapitulating the phenotype of the
primary tumors from which they were isolated and were capable
of self-renewal, even when the tumors originated from transplant
of single tumor cells.
High TIC frequency, lack of an apparent cellular hierarchy and
the inability to prospectively enrich TIC from bulk tumor cell
populations using antibodies to a diversity of cell-surface proteins
are features that have been ascribed to tumor types that do not
follow the cancer stem cell model [47]. The mouse mammary
tumors we analyzed encompass some of these aforementioned
characteristics (viz. high TIC frequency), but also possess features
that are commonly attributed to tumors that follow the cancer
stem cell model (viz. cellular hierarchy). Hence we wondered
whether TIC frequency could be manipulated by propagating
Figure 1. Limiting dilution transplants of dispersed primary MMTV-Neu transgenic mammary tumor cells. (A), Haematoxylin-stained
mammary whole mounts isolated 4 weeks post-transplant reveal tumor-like masses in the fat pads of recipient mice injected with limiting dilutions of
primary tumor cells. The mass of the tumor nodules correlates with the number of tumor cells injected (black arrows). Satellite tumor nodules are
apparent along the needle track (white arrows). The images were photographed at a magnification of 6.4. (B), Tumor nodule appearing in mice
transplanted with a single cell at 4 weeks post-transplantation. The image was photographed at a magnification of 6.4. (C), Macroscopic, palpable
tumors are visible 16 weeks after transplanting single cells into the #4 mammary fat pads of a recipient mouse. (D), Single-cell induced tumors can
develop into macroscopic tumors constituting over 10 million cells.
doi:10.1371/journal.pone.0058151.g001
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TIC-rich primary tumor cells under conditions that either
facilitate stem cell self-renewal or differentiation.
The cancer stem cell model predicts that experimental
conditions facilitating stem cell self-renewal will increase or
maintain TIC frequency, whereas those stimulating differentiation
will reduce their frequency. Consequently, we propagated freshly-
isolated primary tumor cells in either serum-free medium, which
facilitates the survival and self-renewal of human or mouse
mammary epithelial stem/progenitor cells as non-adherent
mammospheres [37,38], or in serum-containing medium, which
stimulates the differentiation of mouse [38,48] and human
mammary epithelial progenitor cells [36]. We previously reported
that primary tumor cells from tumors of the mouse models form
non-adherent spheres, which we termed tumorspheres [34]. A
limiting dilution cell transplantation experiment was performed
with cells dissociated from tumorspheres established from a single
tumor. Tumors or tumor nodules appeared in nearly all the mice
implanted with tumorsphere-derived cells including one of four
mice transplanted with a single tumor cell (Fig. 5; Table 2 –
Tumor identifier 3,736). The latter findings were reminiscent of
the data obtained using primary tumor cells (Fig. 1).
We also compared the frequency of TIC in three additional
independent mammary tumors with that in tumorspheres derived
from these same tumors. The tumorspheres were passaged 3–
4 times during a 2–3 week period to limit any potential genetic
changes in the sphere-resident cells that might alter TIC
frequency. Mice transplanted with dilutions of the dispersed
tumorsphere-derived cells were sacrificed 2–4 months after cell
transplantation. Table 2 illustrates that the frequency of TIC in
the tumorspheres was comparable to that in the primary tumor
cell preparations from which they were derived (compare TIC
frequency in primary tumors 3,727; 3,738; and 3,852 [Table 1]
with companion tumorspheres derived from these tumors
[Table 2]). Moreover, the histology (Fig. 2A, compare subpanels
A1 and A3) and cellular composition of the tumors seeded by
single tumorsphere-derived cells were very similar to those of their
parental tumors arising in the corresponding transgenic strains
(Fig. 2 B and C, compare panels B1 and B3, and C1 and C3).
Individual tumorsphere-derived cells established from primary
tumors of the mT model similarly recapitulated the histology
(Fig. 3A, compare subpanels a1 and a3) and cellular composition
of the primary tumors (Fig. 3B, compare subpanels B1 and B3,
and C1 and C3). Hence culture of primary tumor cells as non-
adherent spheres maintained a high TIC frequency similar to that
of the tumors from which the cells were isolated, and transplant of
tumorsphere-derived cells into syngeneic mice as single cells
yielded tumors that phenocopied the primary tumors from which
they had been established.
To assess any effect of culturing primary tumor cells in serum-
containing medium on TIC frequency, we propagated freshly
isolated primary tumor cells from 3 independent tumors that
occurred in the MMTV-Neu strain in this medium. In pilot
experiments we found that the primary tumor cells adhered and
proliferated resulting in a net expansion of the cell population for
Table 1. Tumor-initiating cell frequencies in primary tumors.
MMTV-Transgene Tumor Identifier
Number of Primary Tumor Cells
Transplanted
Fraction of Primary Tumor
Cells Engrafted TIC Frequency (95% CI)
Neu 3740 100 2/4 1/6
25 1/4 (1/40–1/2)
5 2/6
1 1/6
Neu 3314 100 1/2 1/2
25 4/4 (1/6–1/2)
5 4/6
1 3/6
Neu 3691 100 4/4 1/6
25 4/4 (1/40–1/2)
5 6/6
1 1/6
Neu 3727 100 4/4
25 4/4 1/2
5 2/6 (1/4–1/2)
1 4/6
Neu 3738 100 2/4
25 2/2 1/2
5 4/6 (1/3–1/2)
1 6/8
Neu 3852 100 3/4
25 3/4 1/3
5 1/6 (1/8–1/2)
1 5/8
doi:10.1371/journal.pone.0058151.t001
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4–6 serial passages, but the total tumor cell population sub-
sequently declined with each successive passage and these cultures
could not be sustained beyond 7–9 serial passages. In conse-
quence, we limited propagation of the primary tumor cells to 3
serial passages at 4-day intervals, a protocol similar to that used to
propagate tumorspheres. We observed that independent of the
tumor source between 10,000 and 100,000 tumor cells that had
been propagated in serum-containing medium were required to
elicit a new tumor after transplant into syngeneic female mice
(Table 3 – Tumor identifiers 001, 002 and 406). The tumors
seeded by the cells propagated in serum-containing medium
reproduced the histology of the primary tumors from which the
cells originated (Fig. S1, compare A and B) suggesting that
infrequent TIC in these tumor cell populations seeded tumor
growth. Hence in vitro culture of TIC-rich primary tumor cells in
serum-containing medium for a relatively short period drastically
reduced TIC frequency during a time when the tumor cell
population expanded.
Discussion
The TIC frequency in minimally manipulated bulk tumor cell
populations from tumors occurring in 6 distinct mouse models of
breast cancer have now been determined. The latter models
include: transgenic mice engineered to overexpress Wnt-1 [17,19]
the Neu proto-oncogene [19] or a mutant constitutively-active
form of Neu [20] all under the control of the MMTV promoter;
Figure 2. Tumors arising from transplant of single tumor cells recapitulate the histology and cellular composition characteristic of
the parental tumors. (A), Histopathology of a primary mammary tumor from an MMTV-Neu transgenic mouse (subpanel 1), that of a tumor seeded
by transplant of a single cell (subpanel 2) from the same primary tumor, and that of a tumor derived from transplant of a single cell dissociated from
tumorspheres of the same transgenic strain (subpanel 3). H&E staining of tumor sections illustrates the solid and nodular cytoarchitecture
characteristic of Neu-induced tumors. (B), Immunofluorescence analyses of an MMTV-Neu tumor (subpanel 1), that of a tumor seeded by transplant
of a single cell (subpanel 2) from the same primary tumor, and that of a tumor (subpanel 3) seeded by transplant of a single tumorsphere-derived cell
stained with antibodies to CK8 and CK14. (C), Immunofluorescence analyses of an MMTV-Neu tumor (subpanel 1), that of a tumor seeded by
transplant of a single cell (subpanel 2) from the same primary tumor, and that of a tumor (subpanel 3) seeded by transplant of a single tumorsphere-
derived cell stained with antibodies to CK8 and a-SMA. Note that distinct sections of the same tumor were used for the analyses shown in panels a–c.
Scale bar (inset) represents 40 mm in all panels.
doi:10.1371/journal.pone.0058151.g002
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p53-null mice [18,19,27]; as well as the MMTV-mT and MMTV-
beta-catenin models reported in this study. TIC frequencies in the
MMTV-Wnt-1 model as determined by two different research
groups varied by more than 40 fold [17,19]. TIC frequencies in
two related Neu models similarly varied by 30 fold – between
0.03% (MMTV-mutant Neu) [20] and 0.9% (MMTV-proto-Neu)
[19]. Indeed TIC frequencies reported by the same group in two
different studies published years apart using the p53-null model
varied by 13 fold [18,27].
The TIC frequencies reported previously did not exceed 1% of
the bulk tumor cell population in any of the mouse models and
generally were much lower than this value [17–19,27]. Our
measures of TIC frequency in tumors of the three models that we
examined averaged 30%. The TIC fraction in the tumors arising
in the MMTV-Neu (N202) and MMTV-b-catenin transgenic
strains substantially exceeds those reported previously in the same
(MMTV-Neu) [19] or related (MMTV-Wnt-1) [17,19] models by
30 fold or more. Indeed unpurified single tumor cells from tumors
of each of the three models we examined initiated tumor growth at
high efficiency after orthotopic transplant into immune-competent
syngeneic mice demonstrating that TIC autonomously initiate
tumor growth and implying that TIC must be therapeutically
targeted to achieve durable breast cancer remission. The single cell
seeded tumors recapitulated the cellular composition of the tumors
from which they were isolated and these engrafted tumors could
be serially transplanted demonstrating their capacity for differen-
tiation and self-renewal. The high TIC frequency in the mouse
models we analyzed may be due to the high expression of the
Figure 3. Single transplanted tumor cells isolated from the mammary tumors of MMTV-mT transgenic mice recapitulate the
histology and cellular composition characteristic of their parental tumors. (A), Histology of a primary MMTV-mT tumor (subpanel 1), that of
a tumor resulting from transplanting a single tumor cell from the same tumor (subpanel 2), and that of a tumor that arose from transplantating
a single tumorsphere-derived cell from a tumor of the same transgenic strain (subpanel 3). (B), Immunofluorescence analyses of an MMTV-mT tumor
(subpanel 1), that of a tumor seeded by transplant of a single cell from the same primary tumor (subpanel 2), and that from a tumor resulting from
transplant of a single tumorsphere-derived cell from a tumor of the same transgenic strain stained with antibodies to CK8 and CK14 (subpanel 3). (C),
Immunofluorescence analyses of an MMTV-mT tumor (subpanel 1), that of a tumor seeded by transplant of a single cell from the same primary tumor
(subpanel 2), and that of a tumor resulting from transplant of a single tumorsphere-derived cell from a tumor of the same transgenic strain stained
with antibodies to CK8 and a-SMA (subpanel 3). Note that distinct sections of the same tumor were used for the analyses shown in panels a–c. Scale
bar (inset) represents 40 mm in all panels.
doi:10.1371/journal.pone.0058151.g003
Breast Tumor-Initiating Cells from Mouse Models
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58151
various oncogenes under the control of the MMTV promoter.
High oncogene expression has previously been shown to expand
the repertoire of hematopoietic target cells that are transformed by
MLL-AF9 [49]. The MMTV promoter may similarly effect high
expression of various oncogenes to mammary epithelial cell types
that are ordinarily not susceptible to transformation by these
oncogenes when expressed at lower levels.
The wide discrepancies in TIC frequency in tumors of the same
models reported by various investigators and us likely result from
differences in the experimental procedures used to prepare and
fractionate dispersed tumor cells, and perhaps to the sensitivity of
the tumor cell transplantation assay as practiced in individual
laboratories. Unlike previous measurements of TIC frequency in
mouse mammary tumors we did not use fluorescence activated cell
sorting (FACS) to separate hematopoietic, endothelial and stromal
cells from tumor cells prior to their transplantation, whereas all
previous studies employed FACS to enrich for tumor cells
[19,27,43]. The high pressure of FACS may reduce TIC viability
as reported previously [27,43]. Moreover TIC engraftment may
be aided by non-tumor derived cells such as stromal cells [50]; the
depletion of such cells from the bulk tumor cell population in other
studies may have led to underestimates of TIC frequency.
We used Matrigel as a vehicle to enhance TIC engraftment,
whereas none of the other studies used this agent. Matrigel
reportedly facilitates the engraftment of mouse mammary
epithelial stem and progenitor cells and may have similarly
stimulated the engraftment of TIC and progenitor-like tumor cells
in our transplantation experiments [51]. In this regard we
observed both large (1–2 g wet weight) and small tumors (100–
200 mg wet weight) among recipient mice transplanted with
limiting dilutions of primary tumor cells. However, the small
tumors, which may have been seeded by progenitor-like tumor
cells with limited proliferative potential, constituted only a minor
fraction of all the tumors we identified and were not scored in our
analyses of TIC frequency or analyzed further.
The procedure we used to prepare dispersed tumor cells differed
from those of previous studies; indeed none of the published
studies used the same conditions to dissociate tumor cells from
tumor tissue. Previous work employed only collagenase [18],
collagenase and hyaluronidase [20], and collagenase, hyaluroni-
dase and trypsin [19]. The duration of treatment of minced tumor
tissue with these enzymes also varied ranging between 1 and
5 hours. We used both collagenase and trypsin to dissociate cells
from tumor fragments and incubated the tissue for a period of
30 min following a protocol by Pullan and Streuli [52].
It is conceivable that the conditions we used to prepare tumor
cells may have led to the selective recovery of TICs after filtering
Figure 4. Single transplanted tumor cells isolated from the
mammary tumors of MMTV-b-catenin transgenic mice recapit-
ulate the histology and cellular composition characteristic of
their parental tumors. (A), H&E staining of an MMTV-b-catenin
primary tumor (subpanel 1) and a tumor obtained after transplanting
a single tumor cell originating from the same tumor (subpanel 2). (B),
Immunofluorescence analyses of an MMTV-b-catenin tumor (subpanel
1) and that of a tumor seeded by transplant of a single cell from the
same primary tumor stained with antibodies to CK8 and CK14 (subpanel
2). (C), Immunofluorescence analyses of an MMTV-b-catenin tumor
(subpanel 1) and that of a tumor seeded by transplant of a single cell
from the same primary tumor stained with antibodies to CK8 and a-
SMA (subpanel 2). Note that distinct sections of the same tumor were
used for the analyses shown in panels a–c. Scale bar (inset) represents
40 mm in all panels.
doi:10.1371/journal.pone.0058151.g004
Figure 5. Single tumorsphere-derived cells from tumors of the MMTV-Neu strain seed the growth of tumors after transplantation
into syngeneic FVB/N mice. Haematoxylin-stained mammary whole mounts isolated 4 weeks post-transplant of varying numbers of tumorsphere-
derived cells reveal tumor-like masses in the fat pads of recipient mice. The mass of the tumor nodules directly correlated with the number of injected
tumor cells. The images were photographed at a magnification of 6.4.
doi:10.1371/journal.pone.0058151.g005
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the bulk tumor cells through a 40 mm sieve to remove undigested
tumor fragments and tumor cell aggregates. The yield of tumor
cells from a 1–2 gram tumor arising in the MMTV-Neu (N202)
strain approximated , 2–36108 cells prior to the removal of
tumor cell aggregates by filtration through a 40 mm sieve; ,95%
of these cells were viable. After filtration through the sieve ,20%
of the cells were recovered in the filtrate; ,95% of these cells were
viable. The latter cell yield is in keeping with that reported
previously from the mammary glands of mice using the Pullan and
Streuli protocol [52]. If the frequency of TIC in the Neu-induced
tumors was as high as 1% as reported previously [19], then we
would expect a 5-fold enrichment in the TIC fraction in the filtrate
yielding a ,5% TIC frequency. However, our measurements
yielded a 6 fold higher TIC frequency in the filtrate, which
Table 2. Tumor-initiating cell frequencies in tumorpshere preparations.
MMTV-Transgene Tumor Identifier
Number of Tumorsphere-Derived
Cells Transplanted
Fraction of Tumorsphere-Derived
Cells Engrafted TIC Frequency (95% CI)
Neu 3736 100,000 4/4
10,000 4/4
1,000 6/6
500 4/4
100 12/12 1/3
50 4/4 (1/4–1/2)
25 2/2
10 3/4
5 4/4
1 12/28
Neu 3727 100 4/4
25 4/4 1/5
5 6/6 (1/10–1/3)
1 6/28
Neu 3738 25 3/4 1/3
5 4/6 (1/8–1/2)
1 3/8
Neu 3852 25 3/4 1/3
5 3/8 (1/8–1/2)
1 3/8
doi:10.1371/journal.pone.0058151.t002
Table 3. Tumor-initiating cell frequencies in adherent tumor cell preparations.
MMTV-Transgene Tumor Identifier
Number of Adherent Tumor Cells
Transplanted
Fraction of adherent tumor
cells engrafted TIC Frequency (95% CI)
Neu 001 100,000 1/4 1/392,318 (1/2,765831–1/55,648)
10,000 0/4
1,000 0/4
100 0/4
10 0/4
Neu 002 50,000 4/4 1/20,332
10,000 1/4 (1/54,184
1,000 0/4 -
100 0/4 1/7,629)
10 0/4
Neu 406 10,000 0/4 N/A
1,000 0/4
100 0/4
10 0/4
doi:10.1371/journal.pone.0058151.t003
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averaged ,30%. We also note that the mouse mammary
tumorspheres were dissociated by titruation, and were not filtered
through sieves, yet their resident TIC frequency approximated
that of the primary tumors from which they were established.
Thus whereas we cannot rule out the possibility that the means we
used to isolate dispersed tumor cells enriched for TIC, we doubt
that the high TIC frequencies we observed in the tumors we
examined was due solely to this factor. It is also conceivable that
the protocols used to dissociate the tumors, the quality of the
enzymes employed in each study, and the duration of exposure of
tumor tissue to these reagents used in previous studies may have
led to the selective loss of TIC and may account for the striking
differences in TIC frequencies reported by others and us.
Resolution of the latter will require further study.
It is also not clear whether the extent of progression of the
tumors analyzed in the various studies influenced TIC frequency.
Multiple different TICs may be present during the early stages of
tumorigenesis, but clonal evolution may occur during tumor
progression resulting in the selection of a TIC population with an
increased propensity to self-renew and a decreased capacity to
differentiate [47,53]. The mammary tumors we investigated may
have progressed to a greater extent than those studied by others
and this parameter may account for the higher TIC fraction that
we observed. Evidence for a relationship between tumor pro-
gression and TIC frequency is suggested by recent findings
demonstrating a correlation between the frequency of tumor cell
engraftment and tumor grade in human breast tumors and
melanomas [22,54]. Hence differences in the sensitivity of the
transplantation assays, the quality of the transplanted tumor cell
preparations, the use of Matrigel to facilitate tumor cell
engraftment, and/or perhaps the extent of tumor progression
may account for the disparate TIC frequencies reported by us and
others in the mammary tumors of the same or similar models.
The question arises as to whether the mammary tumors
occurring in the transgenic mice we examined follow the cancer
stem cell model especially in light of their high TIC fraction. All
the mouse breast cancer models studied previously with the sole
exception of the MMTV-Neu transgenic mice have been
suggested to follow this model [17–20]. Consistent with the cancer
stem cell hypothesis tumors arising in either the MMTV-mT or
MMTV-Wnt-1/b-catenin transgenic strains are heterogeneous
comprising cells that express markers of either the luminal or
myoepithelial lineages, the two principal cell lineages in the mouse
mammary gland. By contrast, the tumors of the MMTV-Neu
model are seemingly homogeneous comprising predominantly
luminal-lineage restricted cells [24,25]. Accordingly it has been
suggested that the mT and Wnt-1 induced tumors originate from
stem cells or bipotent progenitor cells, whereas the Neu-induced
tumors may emerge from luminal-restricted progenitor cells
[31,55].
In keeping with the cellular heterogeneity of the tumors in the
mouse models, the use of antibodies to mammary epithelial stem
cell surface markers together with FACS have permitted sorting
mammary tumor cells into tumorigenic and non-tumorigenic
fractions. A very minor tumorigenic cell population can be
separated from the bulk, non-tumorigenic tumor cell fraction using
FACS in the MMTV-Wnt-1 model, analogous to the MMTV-b-
catenin model we studied [17,19]. By contrast, Vaillant et al
reported that whereas the tumors from the MMTV-Neu model,
identical to that which we investigated, also comprised a relatively
minor TIC fraction (,1%), the TIC could not be similarly
separated from the bulk tumor cells using antibodies to CD61,
CD29 and CD24, leading these investigators to suggest that these
tumors do not follow the cancer stem cell model [19]. Whether
other combinations of cell surface markers might permit separa-
tion of TIC from the bulk tumor cell population in tumors of the
MMTV-Neu transgenic strain has not been reported.
In light of the very high TIC frequency in the mouse mammary
tumors we studied, the unavailability of markers that might
facilitate fractionation of TIC from non-tumorigenic cells in the
MMTV-Neu model [19] and the finding that FACS compromises
TIC survival [43], we did not attempt to sort the bulk tumor cell
populations of the models we studied into tumorigenic and non-
tumorigenic fractions. Instead we asked whether other means
might be used to determine whether the tumors we studied
conformed to the cancer stem cell model. To this end we enquired
whether conditions that favor normal stem cell self-renewal or
differentiation might influence TIC frequency. A central tenet of
the cancer stem cell model is that quasi-stable epigenetic
differences distinguish TIC from their differentiating non-tumor-
igenic descendants [9,47].
We found that the TIC frequency of the mammary tumors in
the MMTV-Neu model could be maintained by culturing freshly
isolated tumor cells in chemically-defined, serum-free medium, but
that propagating these cells for a similar period and passage
number in serum-containing medium reduced the TIC fraction by
roughly 4 orders of magnitude. It is noteworthy that only 1% of
primary tumor cells form tumorspheres, and that this fraction of
sphere-forming cells does not vary during serial passage [56].
Hence the vast majority of the dispersed tumor cells do not survive
plating in serum-free medium and because cell proliferation
during sphere formation subsides substantially after 3–4 days in
culture under the growth conditions we employed, there is no net
expansion of the total tumor cell population during serial passage
of bulk tumorsphere cultures. The growth factors in serum-free
medium (FGF-2 and EGF) may sustain self-renewal of TIC and/
or limit their differentiation into highly proliferative progenitor-
like cells. By contrast, the plating efficiency of primary tumor cells
varied between 10%–30% in serum-containing medium and the
cells proliferated resulting in net expansion of the starting cell
population by ,10-fold during their initial serial passage. The
latter findings are consistent with the possibility that serum factors
initiate a differentiation program in TIC resulting in the transient
proliferation of their progenitor like descendants, which culmi-
nates in their aberrant differentiation and consequent loss of
proliferative and tumorigenic capacity. The latter hypothesis is
consistent with the observation that normal mammary epithelial
stem/progenitor cells can be propagated as mammospheres in
serum-free medium, and undergo a differentiation program when
propagated in serum-containing medium [36–38,48]. However,
we have no evidence that the differentiation of TICs leads to their
loss of tumorigenicity in vitro and cannot rule out the possibility
that TICs simply do not survive in serum-containing medium.
It seems unlikely that TIC were diluted by the expansion of
non-tumorigenic cells in serum-containing medium because the
net increase in total cell number was roughly 10-fold, whereas the
decline in TIC frequency was 10,000 fold or greater. The
possibility that fibroblasts present in the primary tumor cell
preparations overgrew the epithelial tumor cells during their
propagation in serum-containing medium seems unlikely because
the vast majority of the cells growing in serum-containing medium
appeared to be epithelial in morphology independent of their
passage history. Because the tumor cells were cultured in vitro in
either growth condition for only 12 days it also seems unlikely that
genetic changes account for their wide difference in TIC
frequency.
At this juncture is not clear what specific factors account for the
difference in TIC fraction between tumors arising in the same
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mouse models reported by different laboratories, or whether the
various models studied follow the cancer stem cell model. Whereas
resolving these matters have therapeutic implications and conse-
quently needs to be critically examined, the high TIC frequency in
mouse mammary tumors and the capacity to maintain TIC-rich
or TIC-depleted tumor cell populations in vitro may afford an
opportunity to identify TIC biomarkers and TIC-targeted
therapeutic agents, especially in view of the technical limitations
inherent in sourcing human breast TIC to this end. Indeed we
have used the mouse mammary tumorspheres and corresponding
normal mouse mammospheres to identify TIC-selective com-
pounds [56,57].
Conclusions
Our results demonstrate that mouse mammary tumors, in-
cluding those arising in transgenic strains thought to conform to
the cancer stem cell model, can comprise a very high TIC
frequency that approach 50% in some tumors. Moreover, we show
that a similarly high TIC frequency can be maintained by
propagating the tumor cells in serum-free medium as non-
adherent tumorspheres. By contrast, culturing the tumor cells for
an identical period in serum-containing medium resulted in
a substantial reduction in TIC frequency. These various tumor cell
sources provide a rich source of tumorigenic or non-tumorigenic
tumor cells for comparative analyses.
Supporting Information
Figure S1 Tumors arising from transplant of tumor cells
propagated in serum-containing medium recapitulate the histology
the parental tumor. (A), Histology of a primary mammary tumor
from an MMTV-Neu transgenic mouse. (B), Histology of a tumor
seeded by transplant of tumor cells from the tumor shown in panel
A that had been propagated in vitro in serum-containing medium.
H&E staining of tumor sections illustrates the cytoarchitecture
characteristic of Neu-induced tumors. Scale bar (inset) represents
40 mm in all panels.
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